Presented by:
Professor of Pediatrics, Hematology and Immunology and Co-Director of the Human Immunology and Immunotherapy Initiative at the University of Colorado School of Medicine
View SlidesT cells genetically modified to express chimeric antigen receptors are highly effective at eradicating malignant B cells resulting in recent approval for the treatment of refractory B cell acute lymphoblastic leukemia in children and B cell lymphoma in adults. However, a substantial number of patients will relapse or not respond and extension of CAR T cell therapy to other forms of cancer has met challenges. Terry’s presentation will review the status of current CAR T cell therapy for human cancer;and, highlight strategies to optimize CAR T cells to improve remission durability and to address barriers to success in other forms of cancer.